Chief Medical Officer · Acumen Pharmaceuticals, Inc. (ABOS)

Eric Siemers

A named executive officer of Acumen Pharmaceuticals in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$637,906

Salary $336,159Stock awards $0

FY2020: $237,600

3rd of 3 named executive officers at Acumen Pharmaceuticals by FY2021 total.

3 named officers on file for Acumen Pharmaceuticals, FY2021

Eric Siemers’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Acumen Pharmaceuticals’s whole pay program stands against its peers

  • Acumen Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ABOS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Eric Siemers’s full pay file as a PDF — free

More than this page: up to 10 years of Eric’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Eric Siemers compensation by year

Acumen Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Acumen Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$180,000$336,159
Bonus$57,600$0
Stock awards$0$0
Option awards$0$177,264
Non-equity incentive$0$124,283
Pension and deferred compensation$0$0
All other$0$200
Total$237,600$637,906

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Acumen Pharmaceuticals, Inc. DEF 14A filed April 27, 2022, accession 0001193125-22-123856, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Acumen Pharmaceuticals, Inc. filed document, accession 0001193125-22-123856. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2022.

$238K
$638K
FY20
FY21
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option310,989—$1.19

Per the Outstanding Equity Awards at Fiscal Year-End table in Acumen Pharmaceuticals, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

15 Form 4 lines since the FY2021 proxy (filed April 27, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-01-22Sale—895$1.82255,371
2026-01-21Sale—2,331$1.80256,266
2026-01-16Grant or award—99,133$0.00258,597
2026-01-16Grant or award derivative—148,700$0.00148,700
2026-01-06Sale—6,834$1.97159,464
2026-01-05Sale—4,000$1.96166,298
2025-01-21Sale10b5-13,219$1.59170,298
2025-01-06Grant or award derivative10b5-1100,300$0.00100,300

The 8 most recent of 15 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Acumen Pharmaceuticals’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Daniel O'ConnellPresident and Chief Executive Officer$1,477,836
Matthew ZugaChief Financial Officer and Chief Business Officer$778,831
Eric Siemers · this pageChief Medical Officer$637,906

The full Acumen Pharmaceuticals compensation record

free company brief

This page is one person within Acumen Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Acumen Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Eric Siemers's compensation dossier · One-time report. No refunds.